The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Novavax (NasdaqGS:NVAX) recently announced preliminary results from its SHIELD-Utah study, showcasing the Novavax COVID-19 vaccine's effectiveness and reduced side effects compared to a competitor's ...

Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Josh Lipton explores some of the top stories on Yahoo Finance's Market Minute. Novavax (NVAX) shares fell after US President Donald Trump's Secretary of Health and Human Services Robert F. Kennedy Jr.

Novavax (NVAX) closed the most recent trading day at $6.01, moving +0.17% from the previous trading session. This change outpaced the S&P 500's 2.36% loss on the day. Elsewhere, the Dow saw a ...

The U.S. Food and Drug Administration (FDA) is still negotiating whether to grant full approval to Novavax's COVID-19 vaccine ...

The Novavax COVID-19 vaccine is set to finally receive full approval from the FDA. The agency said Novavax must collect more ...

CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might still win approval after Health Secretary Robert F.